Drug Monitoring Programs

Henry Siegler

California Polytechnic State University, San Luis Obispo

May 26, 2023

Abstract

Opioid overdose rates have been steadily increasing in the United States since the late 1990s. Prescription Drug Monitoring Programs (PDMPs) are systems that collect and distribute information on controlled substances and are accessible to healthcare providers and authorities. This study estimates the association between establishing an operational PDMP and the overall opioid overdose death rate. Using data from 2000 to 2020 from all 50 states and the District of Columbia, this study evaluates the effectiveness of PDMPs in regulating the distribution of opioids, which is theorized to lead to lower levels of opioid misuse and diversion, and as a result, lower levels of opioid overdoses. Opioid overdose death rate data was collected from the CDC Wonder Database, and data was collected on the year in which an operational PDMP was established in a state. A panel data regression model with state and year-fixed effects is employed, and the results suggest that states with operational PDMPs experience an average of 1.063 fewer opioid overdose deaths per 100,000 people, compared to states without a PDMP. Previous research on this topic has shown mixed findings. This study uses a different set of covariates compared to previous studies over a more extended period and employs the date when the PDMPs became operational, rather than when legislation for PDMPs was established in each state. The results are similar in magnitude to those studies that have found PDMPs to reduce opioid overdoses.

JEL:

Key Words:

**1. Introduction**

The U.S. is currently amid an opioid epidemic, which has been a growing issue over the past 20 years. Opioid overdose deaths have been rapidly increasing since 2000. Opioid overdose deaths rose from 21,089 in 2010 to 47,600 in 2017 (U.S. Department). Since the late 1990s, there have been three waves of opioid overdose deaths, the first being in 1999 when there was a rise in prescription overdose deaths. The second wave started in 2010 due to a rapid increase in heroin overdoses. The third wave began in 2013 due to illicitly manufactured fentanyl and other synthetic opioids (Centers for Disease).

U.S. state governments and the federal government have taken various actions to fight the opioid overdose epidemic by identifying outbreaks, collecting data, and providing care to affected communities. Today, PDMPs are one of these strategies to combat the epidemic, and they are believed to be among the most promising state-level interventions to improve opioid prescribing and reduce opioid diversion. Today, PDMPs are electronic databases that track controlled substance prescriptions in a state and can be accessed by health authorities and healthcare providers. In this research paper, I estimate the association between a state having an operational PDMP and the state’s opioid overdose death rate.

Other research has suggested that the implementation of PDMPs is effective at reducing the supply of prescription drugs, one study found that PDMPs are associated with a 3% decrease in annual morphine milligram equivalents per capita (Brady et al. 2014). The theory is that healthcare providers properly use the PDMPs and restrict the number of opioids they prescribe, specifically to those who already have received enough opioids for their condition. Not only has there been research to suggest that PDMPs reduce the number of opioids prescribed, but some research has shown that PDMPs also reduce the prescription opioid overdose death rate (Cerda et al. 2021). In addition, research on the effect of PDMPs on the overall opioid overdose death rate has suggested that newly implemented programs are associated with lower rates (Patrick et al. 2017). However, findings are mixed, and some studies have found that PDMPs are not associated with decreases in the overdose mortality rate of prescription drugs as well as other drug overdoses (Nam et al. 2017).

Based on my research of PDMPs, I believe that PDMPs are effective tools for helping healthcare providers make more well-informed decisions about prescriptions, thereby reducing the number of prescriptions to those patients who appear to have already been sufficiently prescribed for their condition. I hypothesize that the implementation of PDMPs is associated with a reduction in the opioid overdose death rate in a state and year.

Data were collected on the opioid overdose death rates in each state-year pair from 2000 to 2020 using the CDC Wonder database. Using information from the Prescription Drug Abuse Policy System (PDAPS), the year in which a PDMP became operational in each state was recorded. To control for covariates in the panel data, data were obtained on the median incomes and poverty rates in each state-year pair from the United States Census Bureau. Data were also obtained on the percentage of white people, the unemployment rate, the percentage of people with a bachelor’s degree or higher, and the average age from the IPUMS USA community survey.

Using this data, I constructed a linear panel data regression model with fixed effects for both the state and year dimensions. The dependent variable in this model is the opioid overdose death rate in a state year pair. The variable of interest is an indicator variable equal to one if a state has an operational PDMP implemented in the given year.

In this paper, I first evaluate previous literature and research on the effectiveness of PDMPs. Then, I discuss the economic theory by which PDMPs are theorized to help reduce the opioid overdose death rate. I continue by describing the data that I collected for the regression equation and then I discuss the regression equation. Finally, I provide my results.

**2. Literature Review**

Earlier research provides conflicting evidence that states with PDMPs experience reduced opioid overdose death rates. Several studies on the association between PDMP implementation and both levels of prescription opioid prescribing and opioid overdoses have been conducted.

Brady et al. (2014) investigate the effect of prescription drug monitoring programs (PDMPs) on dispensing prescription opioids in the United States. Using data from each state and the District of Columbia from 1999 to 2008, their research suggests that after adjusting for temporal trends and demographic characteristics, the implementation of a PDMP was associated with a 3% decrease in the annual morphine milligram equivalents (MMEs) per capita, which may lead to a reduction in the number of opioid overdoses. The researchers found that the effect of PDMPs on opioid prescriptions varied greatly across states. The researchers found that the implementation of PDMPs was associated with significantly fewer MMEs dispensed per capita in nine states and a significant increase in the MMEs dispensed per capita in eight states. The study provides valuable insights into the potential effectiveness of PDMPs in reducing the dispensing of prescription opioids, which is an important way in which PDMPs can reduce the number of opioid overdoses. One shortcoming of the study is that it does not assess the potential unintended consequences of PDMPs, such as patients seeking opioids from other sources, including illegal options, or engaging in more dangerous forms of drug use. In addition, the researchers only examined a few characteristics of state PDMP programs and did not investigate the lag between a prescription being dispensed and recorded in the PDMP database and barriers to accessing the data. This study generally provides evidence that implementing PDMPs is effective in reducing the total amount of prescription opioids prescribed in the United States. This is important because prescription opioids are often the reason why many people begin using opioids and develop addictions. Also, prescription opioids are sold to other people who do not have the prescription.

Earlier research on the effect of PDMPs on opioid overdose deaths provides conflicting evidence that states that have recently implemented PDMPs experience reduced negative opioid related outcomes. Reifler et al. (2012) conducted a similar study to investigate whether PDMPs impact state trends in opioid abuse. The researchers used quarterly data from 2003 to 2009 from the RADARS System Poison Center and Opioid Treatment surveillance databases to measure the level of opioid abuse in each state and year. They found that opioid treatment admission increases by 4.9% per quarter on average in states without a PDMP, compared to only 2.6% in states with a PDMP. Also, they conclude that in states without a PDMP, Poison Center exposures increased 1.9% per quarter on average, compared to only 0.2% per quarter on average in states with a PDMP in place. These results suggest that PDMPs are successful programs at reducing overall opioid misuse and abuse. One limitation of this study is that the treatment admission data is subject to self-reporting and selection bias, which may lead to inaccurate numbers. Poison Center specialists record information that is self-reported by callers into a standardized database. Also, the researchers did not evaluate what PDMP characteristics are most effective and which opioids are most impacted.

# Patrick et al. (2017) used an interrupted time-series design to estimate the association of implementation and characteristics of PDMPS with opioid overdose rates. State and year fixed effects account for unmeasured variation at the state level and for time-varying state-level factors, with the state-year pair as the unit of analysis. The annual rate of opioid-related overdose deaths in each state comes from the CDC Wonder database and includes the years from 1999 to 2013. The researchers evaluate the association between opioid overdose death rates and various characteristics of PDMPs, including year or legislative enactment, year of implementation, number of drug schedules monitored, how frequently data was updated, and whether use of the program was mandated. The researchers included both the year of legislative enactment and the year of implementation to isolate the effect of the year of implementation. They also included the interaction of program implementation with time. The researchers conclude that a state newly implementing a program was associated with a decrease of 1.12 opioid-related overdose deaths per 100,000 people per year compared to a state without a program. They also concluded that programs that monitored four or more drug schedules and updated their data at least weekly were associated with greater reductions in opioid related overdose deaths. One shortcoming of the study was that each source of data likely had errors, as opioid overdose-related deaths may be underreported if medical examiners do not have enough evidence of opioid use. Also, the authors acknowledge that it is possible that they did not include all important time-varying state-level factors that are confounding variables, and they did not control for other government programs aimed at reducing opioid deaths. The study results suggest that implementing PDMPs is associated with significant reductions in opioid-related death rates.

# More recently, Cerda et al. (2021) explore the relationship between proactive reporting of state-level prescription drug monitoring programs (PDMPs) and county-level fatal prescription opioid overdoses. The authors use county-level data across 3,109 counties in 49 states from 2002 to 2016 to estimate the effect of PDMPs on opioid overdoses. The study employs Bayesian space-time models which control for differences in the population and opioid prescribing practices between states and over time. Linear distributed lag specifications were used to allow a linear progression of policy associations from instantaneous through 3-year-lagged effects. The results of the study suggest that electronic PDMPs are associated with a significant reduction in prescription opioid overdose deaths after three years. They found that electronic PDMP access was associated with a 2% increase in opioid overdose deaths after the first year but found there to be fewer opioid overdoses in the following three years. They found that proactive PDMPs were associated with fewer deaths attributed to natural or semi-synthetic opioids and methadone compared to states with weak PDMPs. They also concluded that state adoption of PDMPs was associated with fewer opioid deaths overall. Cerda et al. (2017) built on a previous study that used latent transition analysis by examining combinations of PDMP characteristics that were associated with the greatest change in prescription opioid overdose fatalities. However, the shortcoming of the study is that they used certain coding in death certificates to identify the cause of death to construct the county-level overdose rates, which may not reliably identify the drugs involved in overdoses. The research provides evidence that state adoption of PDMPs was associated with fewer prescription opioid deaths overall. The authors provide evidence that proactive reporting PDMPs has a significant impact, compared to weak PDMPS, on reducing fatal prescription opioid overdoses at the county level.

However, other studies have been conducted that do not support the theory that PDMPs reduce opioid-related overdoses. Nam et al. (2017) analyze the effect of PDMPS on the number of fatal drug overdose mortality rates in the United States. The authors used multivariate regression models with state and year fixed effects and state-specific linear time trends. The data in the study comes from 1999 to 2014 and the researchers excluded the 15 states that had implemented PDMPs before 2000. The results break down the association of PDMPs with various types of drugs, and they found that PDMPs were not associated with a decrease in the overdose mortality rate of prescription opioids or in overall drug overdoses. The researchers found that for most categories of drugs, PDMPs were associated with increased overdose mortality rates, but the associations were statistically insignificant. Longer-standing PDMPs were associated with significantly increased mortality rates for legal narcotics and unspecified drugs and illicit drugs. The authors used state-fixed effects to allow each state to serve as a control group. Many state-level time-varying covariates that could be associated with drug overdoses and PDMP implementation were controlled for. This study does provide evidence that PDMPs are not successful in reducing opioid drug overdose death rates. The authors acknowledge that limitations of the study include the limited time frame, potential covariates that were not controlled for, and the PDMP effect is only an average due to binary indicators for PDMP implementation status.

In addition, another study conducted by Paulozzi et al. (2011) suggested that PDMPs were not significantly associated with lower rates of opioid overdose mortality or lower rates of consumption of opioid drugs. They analyze state-level rates of opioid overdose mortality and rates of consumption of opioid drugs using observational data in the United States from 1999 to 2005. The authors used state and year-specific retail distributions of prescription opioids to calculate the morphine milligram equivalents (MMEs) per person as a measure of opioid consumption. Separate panel regression models were run using MMEs and overdose rates as dependent variables. They found that the presence of a PDMP was not a significant predictor of mortality or MME rates. However, they did find a negative regression coefficient for PDMP in the MME model, which indicated a non-statistically significant trend towards lower rates of increase in MME rates in states with a PDMP. The researcher acknowledges that the primary limitation of the study is that they cannot rule out residual confounding, such as states with a predisposition towards drug abuse potentially initially having a higher drug overdose rate that might have made them more likely to establish a PDMP.

**Economic Model/Theory**

PDMPs provide opioid prescribers with more information on the patients they are prescribing to and PDMPs improve prescribers’ ability to identify patients who are more at risk of abusing or overdosing on opioids. The supply of prescription opioids is influenced by the cost of production, regulations, and government policies. PDMPs may limit the number of prescriptions that can be written for certain drugs or require doctors to follow stricter guidelines when prescribing. The theoretical purpose of PDMPs is to regulate the distribution of opioids and to reduce drug diversion, which would lead to a lower supply of prescription drugs overall, and specifically to those most at risk of abusing them. Economic theory suggests that having a lower supply of these drugs, as well as having fewer people exposed to the drugs in the first place, should lead to lower levels of opioid use and as a result, opioid overdoses. If people generally have less access to the drugs, they are less likely to become addicted to them, so the overall demand for opioids should decrease as well over time, which will ultimately result in a reduction in the number of opioid overdose deaths.

PDMPs may take time after their legalization and implementation before they start to influence the opioid overdose death rate. PDMPs may not be effective at reducing the overdose rates for those already abusing opioids before implementation, but they may lead to fewer people being exposed to the drugs in the future and may prevent many people who use the drugs from developing addictions. The assumptions of this model are that prescribers consider information from the PDMPs before prescribing opioids and that a significant amount of the opioids being used by the population come from prescriptions.

Based on the theory of supply and demand, it is expected that the opioid overdose death rates in a state should decrease after some period after the implementation of a PDMP in that given state. The time effect of the implementation of the PDMP on reducing the overdose death rate is unclear and may differ between states depending upon certain factors of the PDMPs.

**3. Data and Methodology**

**Data Source**

This analysis uses observational state-year-level data on the opioid death rate per 100,000 people from 2000 to 2020, which was obtained from the CDC Wonder Database. The opioid death rate will be the outcome variable in the model, and it will measure the level of opioid abuse in each state and year. From the CDC Wonder Database, the ICD-10 Codes that were selected as the multiple causes of death were T40.0-T40.4 and T40.6. We would expect there to be 21 years of data for the 50 states and the District of Columbia, resulting in 1,071 observations. However, there are some state-year combinations where there are not enough overdose deaths to find a reliable death rate, so there are 1,035 observations in the final dataset.

Using information from the Prescription Drug Abuse Policy System (PDAPS), an indicator variable was created to indicate whether or not there was an operational PDMP in place in a given state and year.

To control for covariates in the panel data, I obtained data on the median incomes and poverty rates in each state and year. This data was obtained from the United States Census Bureau. Data were also obtained on the percentage of white people, the unemployment rate, the percentage of people with a bachelor’s degree or higher, and the average age for each state from 2000 to 2020. This data was all obtained from the IPUMS USA community survey. The percentages and estimates were calculated using the person weight variable, which indicates how many people in the US population are represented by a given person in the IPUMS sample.

Figure 1 shows the average overall opioid death rate across all 50 states and the District of Columbia each year. Figure 2 shows the quantiles of the opioid overdose death rates in selected years. In both figures, we can see that opioid death rates have rapidly increased over this time horizon.

**Empirical Regression**

The goal of this research paper is to estimate the effect that implementing PDMPs has on the opioid overdose death rate and to see how that effect may differ depending on the number of years after the PDMP was implemented. Given the differential timing in PDMP implementation, and that by 2013, Missouri was the only state without a PDMP, we will use a panel data model with state-year fixed effects to examine the effect of the implementation of a PDMP in a given state and year on the opioid overdose death rate. I use the panel data regression equation:

Text

Description automatically generated

Where Ys, t is the opioid death rate for state *s* in time *t*, αs are state-fixed effects, and γt are year-fixed effects. *PDMP* is a binary variable equal to 1 for a state in years after PDMP implementation and 0 otherwise. The vector of the covariates is included and contains the following variables: the median income, the poverty rate, the percentage of the population that is white, the unemployment rate, the percentage of the population with a bachelor’s degree or higher, and the average age for each state from 2000 to 2020.

I expect the opioid overdose death rate to decrease after PDMP implementation. Therefore, I would expect the coefficient of *PDMP* to be negative, indicating a decrease in overdose deaths after PDMP implementation.

By including a fixed effects model with both year and state-fixed effects, the model controls for unobserved time-varying and state-specific confounders that could influence the opioid overdose death rate. The model includes the variable PDMP, which captures the immediate effect of PDMP implementation.

Additional investigation will include the interaction terms of PDMP with the covariates to explore how the effects of PDMP on the overdose death rate are associated with the various covariates. I also plan to investigate any potential leading and lagging impacts that implementing a PDMP may have on the opioid overdose rate. Also, I plan to investigate how other aspects of PDMPs, such as when they receive certain features, may impact the opioid overdose rate. I report the coefficient estimates and the robust standard errors in the panel data model.

**4. Results**

Table 1 displays my results from estimating the panel data regression equation with state and year-fixed effects. The dependent variable in the model is the opioid overdose death rate per 100,000 people in a state and year, and the standard errors are robust standard errors that are adjusted for heteroscedasticity. Column (1) of Table 1 displays the results of the regression without any covariates, but with state and year-fixed effects. The PDMP coefficient of -1.114 suggests that states with a PDMP that is operational are estimated to experience an average annual decrease of 1.114 opioid overdose deaths per 100,000 people. This coefficient is significant at a 5% level of significance. Using a robustness check of this estimate, Column (2) of Table 1 includes all the covariates. The additional control variables shrink the PDMP coefficient to -1.063, but the coefficient does remain statistically significant at the 5% level. The relatively small decrease in the magnitude of the coefficient of PDMP suggests that the fixed effects control for most differences between states and time periods.

**5. Conclusion**

Earlier research shows that PDMPs likely are effective at reducing opioid-related deaths as well as the number of opioids prescribed, however, the results of the various studies often conflict with each other. This paper attempts to provide another estimate of the effect that PDMPs have on the opioid overdose death rate by using different covariates, as well as using different interaction variables and aspects of PDMPs to explore the ways in which they are or are not effective. PDMPs provide healthcare providers with reliable information on the prescriptions of their patients, which likely leads to lower levels of opioid diversion and opioid misuse. To account for a wide time period, I account for demographic factors in each state and year, and I use state-level PDMP operation status as the treatment variable.

The preliminary results of my study suggest that states with operational PDMPs are expected to see reductions of about 1 opioid-related overdose per 100,000 people per year. For a state like California, with a population of about 39 million, this would mean that we would expect to see about 415 fewer opioid-related overdoses annually after a PDMP become operational. Future studies could improve upon the results of this paper by collecting more data on health-related covariates such as the number of naloxone medications provided or other opioid-related efforts in states.

Creating well-funded and well-functioning PDMPs is unlikely to solve the opioid epidemic, but the evidence of a significant reduction in the opioid overdose death rate after PDMP implementation is an economically significant reduction and demonstrates that PDMPs are an effective way at starting to combat this problem. Policymakers should consider improving funding for PDMPs and improving interstate operability. These results also suggest that other related efforts to combat the epidemic may also be worthwhile.

**References**

# Brady, J. E., Wunsch, H., DiMaggio, C., Lang, B. H., Giglio, J., & Li, G. (2014). Prescription Drug

# Monitoring and Dispensing of Prescription Opioids. *Public Health Reports (1974-)*, *129*(2), 139–147. <http://www.jstor.org/stable/43775344>

Centers for Disease Control and Prevention. (2022, June 1). *Understanding the opioid overdose epidemic*. Centers for Disease Control and Prevention. Retrieved March 24, 2023, from <https://www.cdc.gov/opioids/basics/epidemic.html#:~:text=The%20first%20wave%20began%20with,overdose%20deaths%20involving%20heroin4>

Cerdá, M., Ponicki, W. R., Smith, N., Rivera-Aguirre, A., Davis, C. S., Marshall, B. D. L., Fink,

D. S., Henry, S. G., Castillo-Carniglia, A., Wintemute, G. J., Gaidus, A., Gruenewald, P. J., & Martins, S. S. (2020). Measuring Relationships Between Proactive Reporting State-level Prescription Drug Monitoring Programs and County-level Fatal Prescription Opioid Overdoses. *Epidemiology (Cambridge, Mass.)*, *31*(1), 32–42. https://pubmed.ncbi.nlm.nih.gov/31596794/

# Nam, Y. H., Shea, D. G., Shi, Y., & Moran, J. R. (2017). State prescription drug monitoring

# programs and fatal drug overdoses. *The American journal of managed care*, *23*(5), 297–303. https://www.ajmc.com/view/state-prescription-drug-monitoring-programs-and-fatal-drug-overdoses

Patrick, S. W., Fry, C. E., Jones, T. F., & Buntin, M. B. (2016). Implementation Of Prescription

Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates. *Health affairs (Project Hope)*, *35*(7), 1324–1332. <https://doi.org/10.1377/hlthaff.2015.1496>

Reifler, L.M., Droz, D., Bailey, J.E., Schnoll, S.H., Fant, R., Dart, R.C. and Bucher Bartelson, B.

(2012), Do Prescription Monitoring Programs Impact State Trends in Opioid Abuse/Misuse?. Pain Medicine, 13: 434-442. <https://doi-org.ezproxy.lib.calpoly.edu/10.1111/j.1526-4637.2012.01327.x>

U.S. Department of Health and Human Services. (2023, March 8). *Drug Overdose Death Rates*.

National Institutes of Health. Retrieved March 24, 2023, from <https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates>

<https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/nhe-fact-sheet>

Figure 1

Chart, line chart

Description automatically generated

Figure 2

A picture containing text, indoor, screenshot

Description automatically generated

Table

Description automatically generated